Q1 2025 · 13F-HR
Decheng Capital LLCholdings as filed
Filed 2025-05-08 · accession 0001104659-25-045686
$356.5M
Reported value
27
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $156.0M | 43.8% | 6,371,669 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio Inc. | $45.7M | 12.8% | 25,954,439 | Common | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $29.4M | 8.25% | 3,917,299 | Common | SOLE |
| 91678A107 | UPB | Upstream Bio Inc. | $20.1M | 5.64% | 3,285,293 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $15.8M | 4.42% | 770,000 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $11.7M | 3.29% | 65,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC(NSM) | $8.0M | 2.24% | 226,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS NV | $8.0M | 2.23% | 189,098 | Common | SOLE |
| G10830100 | BYSI | BeyondSpring Inc. | $7.0M | 1.96% | 4,882,651 | Common | SOLE |
| G4444C102 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $6.7M | 1.88% | 171,600 | Common | SOLE |
| 55083R104 | — | Lyell Immunopharma, Inc. | $6.4M | 1.80% | 11,909,341 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences, Inc | $6.3M | 1.78% | 808,789 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $6.2M | 1.73% | 4,041,736 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $6.0M | 1.67% | 177,958 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $4.0M | 1.13% | 100,000 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP-ADR | $3.4M | 0.95% | 100,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $3.3M | 0.92% | 50,000 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals Inc. | $3.2M | 0.90% | 2,019,762 | Common | SOLE |
| 05153U107 | AURA | Aura Biosciences, Inc. | $3.0M | 0.85% | 515,555 | Common | SOLE |
| 09075V102 | BNTX | Biontech SE-ADR | $1.8M | 0.51% | 20,000 | Common | SOLE |
| 29446K106 | EQ | Equillium Inc. | $1.7M | 0.49% | 4,447,308 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $1.1M | 0.30% | 335,515 | Common | SOLE |
| 452327109 | ILMN | Illumnia, Inc. | $932,166 | 0.26% | 11,749 | Common | SOLE |
| 747324101 | PYXS | Pyxis Oncology, Inc (formerly Apexigen) | $320,241 | 0.09% | 326,810 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $247,329 | 0.07% | 9,684 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $107,970 | 0.03% | 4,495 | Common | SOLE |
| 67080N119 | NUVB/WS | Nuvation Bio Inc. | $43,990 | 0.01% | 646,057 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.